BRADFORD CLARK DICKERSON
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology BOSTON, MA NPI 1184615700
Browse related groups: Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology MA Eli Lilly and Company All categories
General Payments — all program years on this page
$75,644.39
- Category: General Payments
- Program years: PY2018–2024
- Record count: 36
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $20,274.65 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $20,250.00 | 7 |
| Food and Beverage | $24.65 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Eli Lilly and Company | $12,035.00 | 4 |
| Biogen, Inc. | $4,819.65 | 2 |
| ACADIA Pharmaceuticals Inc | $1,800.00 | 1 |
| EISAI INC. | $1,620.00 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1104830482 | Biogen, Inc. | $24.65 | 11/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1104836018 | Biogen, Inc. | $4,795.00 | 12/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1110733993 | Eisai Inc. | $1,620.00 | 02/27/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1136017683 | Eli Lilly and Company | $3,915.00 | 02/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1136071211 | Eli Lilly and Company | $3,516.25 | 02/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1136071213 | Eli Lilly and Company | $543.75 | 10/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1136072299 | Eli Lilly and Company | $4,060.00 | 04/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1147967926 | ACADIA Pharmaceuticals Inc | $1,800.00 | 01/22/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.